New diabetes shot enters early human testing
NCT ID NCT07032688
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 24 times
Summary
This early-stage study tests a new injectable drug called SHR-3167 in 55 adults with type 2 diabetes. The goal is to measure how the drug moves through the body and how it affects blood sugar levels. Researchers will also monitor for side effects, including low blood sugar events. Participants must be 18-59 years old and diagnosed with type 2 diabetes for at least 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 200433, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.